NASDAQ:ATXS Astria Therapeutics (ATXS) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free ATXS Stock Alerts $9.64 -0.16 (-1.63%) (As of 04:17 PM ET) Add Compare Share Share Today's Range$9.51▼$9.9750-Day Range$9.75▼$16.6952-Week Range$4.26▼$16.90Volume739,331 shsAverage Volume978,657 shsMarket Capitalization$529.24 millionP/E RatioN/ADividend YieldN/APrice Target$21.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Astria Therapeutics alerts: Email Address Astria Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside116.8% Upside$21.25 Price TargetShort InterestBearish11.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.09Based on 4 Articles This WeekInsider TradingAcquiring Shares$30 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.55) to ($1.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.49 out of 5 starsMedical Sector605th out of 910 stocksPharmaceutical Preparations Industry275th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAstria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAstria Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.37% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Astria Therapeutics has recently increased by 151.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATXS. Previous Next 1.6 News and Social Media Coverage News SentimentAstria Therapeutics has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Astria Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ATXS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows6 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have bought 26,830.52% more of their company's stock than they have sold. Specifically, they have bought $29,999,522.00 in company stock and sold $111,396.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.55) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astria Therapeutics is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Astria Therapeutics is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Astria Therapeutics Stock (NASDAQ:ATXS)Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Read More ATXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXS Stock News HeadlinesApril 9, 2024 | businesswire.comAstria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsApril 3, 2024 | finance.yahoo.comChief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)April 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 26, 2024 | markets.businessinsider.comBuy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial ResultsMarch 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Astria Therapeutics on Promising STAR-0215 Data and Market PotentialMarch 25, 2024 | markets.businessinsider.comAstria Therapeutics Reports Positive Initial Results From ALPHA-STAR Trial - Quick FactsMarch 25, 2024 | finance.yahoo.comAstria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAEApril 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 23, 2024 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the companyMarch 15, 2024 | finance.yahoo.comATXS Apr 2024 2.500 putMarch 5, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Astria Therapeutics (ATXS)March 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Astria Therapeutics (ATXS)March 4, 2024 | businesswire.comAstria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateFebruary 27, 2024 | finance.yahoo.comATXS Oct 2024 22.500 callFebruary 20, 2024 | finance.yahoo.comAstria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 20, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 17, 2024 | finance.yahoo.comATXS Mar 2024 22.500 callFebruary 17, 2024 | finance.yahoo.comATXS Mar 2024 12.500 callFebruary 6, 2024 | finance.yahoo.comAstria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 1, 2024 | msn.comAstria Therapeutics Announces Offering to Fund Future OperationsJanuary 30, 2024 | finance.yahoo.comChief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics IncJanuary 30, 2024 | finance.yahoo.comAstria Therapeutics Announces Pricing of $125 Million Underwritten OfferingDecember 16, 2023 | msn.comAstria Therapeutics files $500M mixed securities shelfNovember 27, 2023 | finance.yahoo.comAstria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy CongressNovember 24, 2023 | benzinga.comAstria Therapeutics Stock (NASDAQ:ATXS) Earnings Dates and Earning CallsSee More Headlines Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXS CUSIPN/A CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees59Year Founded2008Price Target and Rating Average Stock Price Target$21.75 High Stock Price Target$27.00 Low Stock Price Target$17.00 Potential Upside/Downside+121.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.65% Return on Assets-33.37% Debt Debt-to-Equity RatioN/A Current Ratio21.73 Quick Ratio21.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book2.94Miscellaneous Outstanding Shares54,900,000Free Float53,036,000Market Cap$538.02 million OptionableOptionable Beta0.69 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Jill C. Milne Ph.D. (Age 56)Co-Founder, CEO, President & Director Comp: $928.52kMr. Benjamin S. Harshbarger J.D. (Age 55)Chief Legal Officer Comp: $621.91kMr. Noah C. Clauser CPA (Age 50)CFO & Treasurer Comp: $508.79kMs. Keri McGrailSenior Vice President of Human ResourcesMs. Andrea L. MatthewsChief Business OfficerMr. Andrew A. Komjathy (Age 60)Chief Commercial Officer Dr. Christopher J. Morabito M.D. (Age 53)Chief Medical Officer Mr. John RueschSenior Vice President of Pharmaceutical Sciences & Technical OperationsMore ExecutivesKey CompetitorsNuvation BioNYSE:NUVBLyell ImmunopharmaNASDAQ:LYELOlema PharmaceuticalsNASDAQ:OLMAMineralys TherapeuticsNASDAQ:MLYSVerve TherapeuticsNASDAQ:VERVView All CompetitorsInsiders & InstitutionsVivo Capital LLCSold 153,700 shares on 4/22/2024Ownership: 4.242%Perceptive Advisors LLCBought 1,814,608 shares on 2/26/2024Ownership: 9.032%ADAR1 Capital Management LLCBought 191,251 shares on 2/14/2024Ownership: 0.431%Armistice Capital LLCBought 1,578,000 shares on 2/13/2024Ownership: 3.560%Affinity Asset Advisors LLCBought 466,165 shares on 2/13/2024Ownership: 3.308%View All Insider TransactionsView All Institutional Transactions ATXS Stock Analysis - Frequently Asked Questions Should I buy or sell Astria Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATXS shares. View ATXS analyst ratings or view top-rated stocks. What is Astria Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 1-year price objectives for Astria Therapeutics' stock. Their ATXS share price targets range from $16.00 to $27.00. On average, they predict the company's stock price to reach $21.25 in the next twelve months. This suggests a possible upside of 116.8% from the stock's current price. View analysts price targets for ATXS or view top-rated stocks among Wall Street analysts. How have ATXS shares performed in 2024? Astria Therapeutics' stock was trading at $7.68 on January 1st, 2024. Since then, ATXS shares have increased by 27.6% and is now trading at $9.80. View the best growth stocks for 2024 here. When is Astria Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ATXS earnings forecast. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) released its quarterly earnings data on Monday, March, 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.08. When did Astria Therapeutics' stock split? Astria Therapeutics shares reverse split before market open on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. Who are Astria Therapeutics' major shareholders? Astria Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vivo Capital LLC (4.24%). Insiders that own company stock include Andrew Komjathy, Christopher Morabito and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest MetalsIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
